# Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

> **NCT01577550** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 39 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BI 655066 (very high i.v. dose)
- **DRUG:** Placebo, i.v.
- **DRUG:** BI 655066 (high s.c. dose)
- **DRUG:** BI 655066 (low i.v. dose)
- **DRUG:** BI 655066 (high medium i.v. dose)
- **DRUG:** BI 655066 (very low i.v. dose)
- **DRUG:** BI 655066 (low s.c. dose)
- **DRUG:** BI 655066 (high i.v. dose)
- **DRUG:** Placebo, s.c.
- **DRUG:** BI 655066 (low medium i.v. dose)

## Key facts

- **NCT ID:** NCT01577550
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-10
- **Final completion:** 2014-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577550, "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01577550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*